ERBB2 and gastroesophageal junction adenocarcinoma: GEJ adenocarcinoma alone accounts for 21% (n=14) of all cases (with HER2 positivity of 21%); proximal tumours other than GEJ tumours accounts for 18% (HER2 positivity of 34%), which is highly significant (P=0.002).